Investigational Epcoritamab (Duobody® Cd3xcd20) Monotherapy Achieves High Overall And Complete Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) In Preliminary Analysis
Investigational Epcoritamab (Duobody® Cd3xcd20) Monotherapy Achieves High Overall And Complete Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) In Preliminary Analysis . (MENAFN - GlobeNewsWire - Nasdaq)   Media Release    COPENHAGEN, Denmark; December 8, 2024      Preliminary analyses from the EPCORE   –   CLL-1 trial demonstrates overall response rate (ORR) of 61 ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968653/Investigational-Epcoritamab-Duobody-Cd3xcd20-Monotherapy-Achieves-High-Overall-And-Complete-Response-Rates-In-Clinical-Trial-Of-Patients-With-Relapsed-Or-Refractory-RR-Chronic-Lymphocytic-Leukemia-CLL-In-Preliminary-Analysis
2024-12-08
rss
(MENAFN - GlobeNewsWire - Nasdaq)   Media Release    COPENHAGEN, Denmark; December 8, 2024      Preliminary analyses from the EPCORE   –   CLL-1 trial demonstrates overall response rate (ORR) of 61 ...
Investigational Epcoritamab (Duobody® Cd3xcd20) Monotherapy Achieves High Overall And Complete Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) In Preliminary Analysis